Literature DB >> 22237755

Apathy in Parkinson's disease: diagnostic and etiological dilemmas.

Sergio E Starkstein1.   

Abstract

About one-third of patients with Parkinson's disease (PD) are diagnosed with apathy in cross-sectional studies. However, once patients with concomitant depression and dementia are excluded, the frequency of apathy drops to 5% to 10%. Several scales have been recommended to rate apathy in PD, but specific psychiatric interviews have not been developed, and recently proposed standardized diagnostic criteria are still in the validation process. Most studies assessing the association between subthalamic deep brain stimulation (STN-DBS) and apathy have reported a relative increase in the frequency and severity of apathy, although discrepant findings have also been reported. Several mechanisms to explain apathy in PD have been proposed, from dopaminergic imbalances in frontal-basal ganglia circuits to dysfunction of nondopaminergic circuits and the cingulate gyrus. Future studies should provide reliable and valid instruments to diagnose apathy in PD, and should examine the mechanism of apathy accounting for relevant confounders, such as depression and cognitive deficits, and important contextual factors. Finally, treatment for apathy in PD should not be restricted to psychoactive drugs, but should also include nonpharmacological techniques such as psychotherapy and occupational therapy.
Copyright © 2012 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22237755     DOI: 10.1002/mds.24061

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  19 in total

1.  Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.

Authors:  Jesús Pérez-Pérez; Javier Pagonabarraga; Saül Martínez-Horta; Ramón Fernández-Bobadilla; Salvador Sierra; Berta Pascual-Sedano; Alexandre Gironell; Jaime Kulisevsky
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

2.  Motivational modes and learning in Parkinson's disease.

Authors:  Karin Foerde; Erin Kendall Braun; E Tory Higgins; Daphna Shohamy
Journal:  Soc Cogn Affect Neurosci       Date:  2014-12-30       Impact factor: 3.436

Review 3.  Assessment and Management of Neuropsychiatric Symptoms in Parkinson's Disease.

Authors:  Christoph Mueller; Anto P Rajkumar; Yi Min Wan; Latha Velayudhan; Dominic Ffytche; Kallol Ray Chaudhuri; Dag Aarsland
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

Review 4.  Impulsivity and apathy in Parkinson's disease.

Authors:  Nihal Sinha; Sanjay Manohar; Masud Husain
Journal:  J Neuropsychol       Date:  2013-04-29       Impact factor: 2.864

Review 5.  Apathy: a neurocircuitry model based on frontotemporal dementia.

Authors:  Simon Ducharme; Bruce H Price; Bradford C Dickerson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-10-24       Impact factor: 10.154

6.  Anxiety and depression in Parkinson's disease.

Authors:  Atbin Djamshidian; Joseph H Friedman
Journal:  Curr Treat Options Neurol       Date:  2014-04       Impact factor: 3.598

7.  Apathy and associated factors in Mexican patients with Parkinson's disease.

Authors:  Mayela Rodríguez-Violante; Paulina González-Latapi; Amin Cervantes-Arriaga; Daniel Martínez-Ramírez; Salvador Velázquez-Osuna; Azyadeh Camacho-Ordoñez
Journal:  Neurol Sci       Date:  2013-12-05       Impact factor: 3.307

Review 8.  Management of motor and non-motor symptoms in Parkinson's disease.

Authors:  Fabienne Sprenger; Werner Poewe
Journal:  CNS Drugs       Date:  2013-04       Impact factor: 5.749

9.  Deep brain stimulation and cognitive decline in Parkinson's disease: a clinical review.

Authors:  João Massano; Carolina Garrett
Journal:  Front Neurol       Date:  2012-04-26       Impact factor: 4.003

Review 10.  Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease.

Authors:  Mine Silindir Gunay; A Yekta Ozer; Sylvie Chalon
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.